William Blair Reaffirms Outperform Rating for Telix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX)

Telix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX)‘s stock had its “outperform” rating reiterated by William Blair in a research note issued on Wednesday,RTT News reports.

Separately, UBS Group raised their price target on shares of Telix Pharmaceuticals Limited American Depositary Shares from $21.00 to $22.00 and gave the company a “buy” rating in a research note on Monday, January 27th.

Telix Pharmaceuticals Limited American Depositary Shares Stock Performance

Shares of Telix Pharmaceuticals Limited American Depositary Shares stock traded up $0.30 during trading on Wednesday, reaching $17.05. 13,383 shares of the company’s stock were exchanged, compared to its average volume of 27,834. Telix Pharmaceuticals Limited American Depositary Shares has a 1-year low of $14.01 and a 1-year high of $30.36. The company has a 50-day simple moving average of $17.35.

Telix Pharmaceuticals Limited American Depositary Shares Company Profile

Telix Pharmaceuticals Ltd. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals.